ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.61
+2.01%13
Insider buys (3m)
7
Insider sells (3m)
$4.2M
Net value (3m)
-9.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Aslan Fred · director, officer: Chief Executive Officer | A-Award | 315,000 | $8.91 |
| Sep 15, 2026 | Aslan Fred · director, officer: Chief Executive Officer | A-Award | 110,000 | $0.00 |
| Sep 14, 2026 | Aslan Fred · director, officer: Chief Executive Officer | A-Award | 45,000 | $0.00 |
| Sep 14, 2026 | MOORE ALISON · director | A-Award | 16,250 | $10 |
| Sep 14, 2026 | Baker Daniel G. · director | A-Award | 16,250 | $10 |
| Sep 14, 2026 | DANIELS BRIAN · director | A-Award | 16,250 | $10 |
| Sep 14, 2026 | HOUGEN ELIZABETH L · director | A-Award | 16,250 | $10 |
| Sep 14, 2026 | Sorg Elaine K. · director | A-Award | 16,250 | $10 |
| Sep 14, 2026 | RA CAPITAL MANAGEMENT, L.P. · director, 10 percent owner: | A-Award | 16,250 | $10 |
| Sep 14, 2026 | Stoppel Laura · director | A-Award | 16,250 | $10 |
| Sep 14, 2026 | Aslan Fred · director, officer: Chief Executive Officer | A-Award | 155,000 | $10 |
| Sep 11, 2026 | Miralles Gines Diego · officer: President & Head of R&D | A-Award | 135,000 | $11 |
| Sep 11, 2026 | Banerjee Subhashis · officer: Chief Medical Officer | A-Award | 85,000 | $11 |
| Sep 11, 2026 | Banerjee Subhashis · officer: Chief Medical Officer | A-Award | 30,000 | $0.00 |
| Sep 11, 2026 | Bush Jennifer · officer: COO, CLO, Compliance Officer | A-Award | 135,000 | $11 |
| Sep 11, 2026 | Bush Jennifer · officer: COO, CLO, Compliance Officer | A-Award | 45,000 | $0.00 |
| Sep 11, 2026 | Horan Christopher · officer: Chief Tech Operations Officer | A-Award | 120,000 | $11 |
| Sep 11, 2026 | Horan Christopher · officer: Chief Tech Operations Officer | A-Award | 40,000 | $0.00 |
| Sep 11, 2026 | Miralles Gines Diego · officer: President & Head of R&D | A-Award | 45,000 | $0.00 |
| Sep 9, 2026 | Aslan Fred · director, officer: Chief Executive Officer | Sale | 23,429 | $11 |
| Sep 8, 2026 | MOORE ALISON · director | A-Award | 13,750 | $11 |
| Sep 8, 2026 | Baker Daniel G. · director | A-Award | 13,750 | $11 |
| Sep 8, 2026 | DANIELS BRIAN · director | A-Award | 13,750 | $11 |
| Sep 8, 2026 | HOUGEN ELIZABETH L · director | A-Award | 13,750 | $11 |
| Sep 8, 2026 | Sorg Elaine K. · director | A-Award | 13,750 | $11 |
| Sep 8, 2026 | Stoppel Laura · director | A-Award | 13,750 | $11 |
| Sep 8, 2026 | RA CAPITAL MANAGEMENT, L.P. · director, 10 percent owner: | A-Award | 13,750 | $11 |
| Sep 4, 2026 | Horan Christopher · officer: Chief Tech Operations Officer | Sale | 10,366 | $11 |
| Sep 4, 2026 | Aslan Fred · director, officer: Chief Executive Officer | Sale | 61,888 | $11 |
| Sep 4, 2026 | Banerjee Subhashis · officer: Chief Medical Officer | Sale | 1,100 | $11 |
Institutional positioning
13F filings over the trailing two quarters
New 51Increased 28Reduced 15Sold out 7
| Filer | Action | Shares | Filed |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Increased | 17,955,642 | Aug 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 9,853,302 | May 15, 2026 |
| VIKING GLOBAL INVESTORS LP | New Position | 2,604,166 | Aug 14, 2026 |
| Blackstone Inc. | New Position | 2,403,437 | Aug 14, 2026 |
| 5AM Venture Management, LLC | Unchanged | 2,353,304 | Aug 14, 2026 |
| 5AM VENTURE MANAGEMENT, LLC | Unchanged | 2,353,304 | May 15, 2026 |
| VR Adviser, LLC | Increased | 2,043,596 | Aug 14, 2026 |
| FRANKLIN RESOURCES INC | Increased | 1,997,223 | Aug 13, 2026 |
| Caligan Partners LP | New Position | 1,736,111 | Aug 14, 2026 |
| VR ADVISER, LLC | Unchanged | 1,609,569 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 981,815 | Aug 13, 2026 |
| Samsara BioCapital, LLC | New Position | 954,861 | Aug 14, 2026 |
| Blue Owl Capital Holdings LP | New Position | 874,542 | Aug 11, 2026 |
| Propel Bio Management, LLC | Increased | 696,436 | Aug 13, 2026 |
| BlackRock, Inc. | Increased | 694,726 | Aug 7, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 15, 2026